Skip to content

Study · Randomized controlled trial · n = 40 · 2005

7 results

Growth hormone treatment reduces abdominal visceral fat in postmenopausal women with abdominal obesity: a 12-month placebo-controlled trial.

Franco C, Brandberg J, Lönn L, Andersson B, Bengtsson BA, Johannsson G

The Journal of clinical endocrinology and metabolism14 Dec 2004Cited by 100 (Europe PMC)

PMID15598680 (opens in a new tab)DOI10.1210/jc.2004-1657 (opens in a new tab)PepBankPUB-15598680
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women with abdominal obesity, GH reduced visceral fat mass compared with placebo.

    In plain wordsIn postmenopausal women with abdominal obesity, GH reduced visceral fat mass compared with placebo.

    Peptide
    HGH (somatotropin)
    Outcome
    DecreaseVisceral fat mass
    Study

    n = 40

    Comparator
    Placebo
    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    0.67 mg/d · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    GH treatment reduced visceral fat mass, increased thigh muscle area, and reduced total and low-density lipoprotein cholesterol compared with placebo.
    1 context sentence
    Summary · context
    Forty postmenopausal women with abdominal obesity participated in a randomized, double-blind, placebo-controlled, 12-month trial with GH (0.67 mg/d).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women with abdominal obesity, GH increased thigh muscle area compared with placebo.

    In plain wordsIn postmenopausal women with abdominal obesity, GH increased thigh muscle area compared with placebo.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseThigh muscle area
    Study

    n = 40

    Comparator
    Placebo
    Outcome group
    Body composition · Musculoskeletal
    Studied dose
    0.67 mg/d · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    GH treatment reduced visceral fat mass, increased thigh muscle area, and reduced total and low-density lipoprotein cholesterol compared with placebo.
    1 context sentence
    Summary · context
    Forty postmenopausal women with abdominal obesity participated in a randomized, double-blind, placebo-controlled, 12-month trial with GH (0.67 mg/d).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women with abdominal obesity, GH reduced total cholesterol compared with placebo.

    In plain wordsIn postmenopausal women with abdominal obesity, GH reduced total cholesterol compared with placebo.

    Peptide
    HGH (somatotropin)
    Outcome
    DecreaseTotal cholesterol
    Study

    n = 40

    Comparator
    Placebo
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    0.67 mg/d · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    GH treatment reduced visceral fat mass, increased thigh muscle area, and reduced total and low-density lipoprotein cholesterol compared with placebo.
    1 context sentence
    Summary · context
    Forty postmenopausal women with abdominal obesity participated in a randomized, double-blind, placebo-controlled, 12-month trial with GH (0.67 mg/d).
  4. 04HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women with abdominal obesity, GH reduced low-density lipoprotein cholesterol compared with placebo.

    In plain wordsIn postmenopausal women with abdominal obesity, GH reduced LDL cholesterol compared with placebo.

    Peptide
    HGH (somatotropin)
    Outcome
    DecreaseLDL cholesterol
    Study

    n = 40

    Comparator
    Placebo
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    0.67 mg/d · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    GH treatment reduced visceral fat mass, increased thigh muscle area, and reduced total and low-density lipoprotein cholesterol compared with placebo.
    1 context sentence
    Summary · context
    Forty postmenopausal women with abdominal obesity participated in a randomized, double-blind, placebo-controlled, 12-month trial with GH (0.67 mg/d).
  5. 05HumanNon-randomized trialEfficacy outcome

    In postmenopausal women with abdominal obesity, insulin sensitivity increased after 12 months of GH compared with baseline.

    In plain wordsIn postmenopausal women with abdominal obesity, insulin sensitivity increased after GH treatment compared with baseline.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseInsulin sensitivity
    Study

    n: not reported in source

    Comparator
    Baseline
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.67 mg/d · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Insulin sensitivity was increased at 12 months compared with baseline values in the GH-treated group.
    1 context sentence
    Summary · context
    Forty postmenopausal women with abdominal obesity participated in a randomized, double-blind, placebo-controlled, 12-month trial with GH (0.67 mg/d).
  6. 06HumanObservational studyMechanism

    In GH-treated postmenopausal women with abdominal obesity, lower baseline glucose disposal correlated with greater insulin sensitivity improvement (r = -0.68; P < 0.001).

    In plain wordsIn GH-treated postmenopausal women with abdominal obesity, lower baseline glucose disposal was linked to greater improvement in insulin sensitivity.

    Peptide
    HGH (somatotropin)
    Outcome
    Not applicableBaseline glucose disposal and insulin sensitivity improvement
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.67 mg/d · 12 monthsAs given in this study (human).

    Measurements

    Correlation coefficient between baseline GDR and improvement in insulin sensitivity
    −0.68 r
    GH-treated group only
    P value
    < 0.001 P
    GH-treated group only

    Source sentences

    Summary
    In the GH-treated group only, a low baseline GDR was correlated with a more marked improvement in insulin sensitivity (r = -0.68; P < 0.001).
    1 context sentence
    Summary · context
    Forty postmenopausal women with abdominal obesity participated in a randomized, double-blind, placebo-controlled, 12-month trial with GH (0.67 mg/d).
  7. 07HumanObservational studyMechanism

    In GH-treated postmenopausal women with abdominal obesity, glucose disposal changes correlated positively with liver attenuation changes (r = 0.7; P < 0.001).

    In plain wordsIn GH-treated postmenopausal women with abdominal obesity, changes in glucose disposal were linked to changes in a liver fat measure.

    Peptide
    HGH (somatotropin)
    Outcome
    Not applicableGlucose disposal change and hepatic fat marker
    Study

    n: not reported in source

    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    0.67 mg/d · 12 monthsAs given in this study (human).

    Measurements

    Correlation coefficient between change in GDR and change in liver attenuation
    0.7 r
    GH-treated group, baseline to 12 months
    P value
    < 0.001 P
    GH-treated group, baseline to 12 months

    Source sentences

    Summary
    A positive correlation was found between changes in GDR and liver attenuation as a measure of hepatic fat content between baseline and 12 months (r = 0.7; P < 0.001) in the GH-treated group.
    1 context sentence
    Summary · context
    Forty postmenopausal women with abdominal obesity participated in a randomized, double-blind, placebo-controlled, 12-month trial with GH (0.67 mg/d).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.